Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children87310.24287/1726-1708-2024-23-2-158-166SCHOOL ON TRANSPLANTATION AND CELLUL AR THERAPYШКОЛА ПО ТРАНСПЛАНТАЦИИ И КЛЕТОЧНОЙ ТЕРАПИИChronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantationХроническая реакция «трансплантат против хозяина» после аллогенной трансплантации гемопоэтических стволовых клетокhttps://orcid.org/0000-0002-0566-053XSkvortsovaYu. V.СкворцоваЮ. В.
Russian Federation

Yulia V. Skvortsova, Dr. Med. Sci., a hematologist, Deputy Head of Hematopoietic Stem Cell Transplantation Department №2 

: 1 Samory Mashela St., Moscow 117997, Russia

 

Скворцова Юлия Валериевна, д-р мед. наук, врач-гематолог, заместитель заведующего отделением трансплантации гемопоэтических стволовых клеток №2

117997, Москва, ул. Саморы Машела, 1 

yuscvo@mail.ruDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России0807202423215816622072024Copyright ©; 2025, «D. Rogachev NMRCPHOI»Copyright ©; 2025, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2025«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/873

Chronic graft-versus-host disease (GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation (HSCT) caused by immune dysregulation leading to multisystem involvement resulting in tissue sclerosis. This is a long-term complication that can significantly affect the quality of life of HSCT recipients due to secondary immunodeficiency associated with combined immunosuppressive therapy, impaired organ function and even disability. In addition to active prophylaxis for chronic GVHD, regular follow-up of patients is necessary for early detection of signs and symptoms of GVHD to enable timely and effective treatment. Here, we present a brief overview of novel approaches to diagnosis, classification, and staging of chronic GVHD, as well as current prophylaxis and treatment options.

Хроническая реакция «трансплантат против хозяина» (РТПХ) является тяжелым осложнением аллогенной трансплантации гемопоэтических стволовых клеток (ТГСК), в основе которого лежит иммунная дисрегуляция, приводящая к мультисистемному поражению с исходом в склерозирование тканей. Данное осложнение пролонгировано во времени и существенно нарушает качество жизни реципиентов ТГСК вследствие формирования вторичного иммунодефицита на фоне комбинированной иммуносупрессивной терапии, ограничения функций и реже – инвалидизации. Помимо активной профилактики хронической РТПХ необходим регулярный мониторинг пациентов для своевременного выявления первых признаков данного осложнения и проведения эффективной терапии. В кратком обзоре хронической РТПХ приведены новые подходы к определению и стадированию, а также указаны современные способы ее предотвращения и лечения.

chronic graft-versus-host diseaseallogeneic hematopoietic stem cell transplantationхроническая реакция «трансплантат против хозяина»аллогенная трансплантация гемопоэтических стволовых клетокZeiser R., Blazar B.R. Acute graftversus-host disease Biology, Prevention and Therapy. New Engl J Med 2017; 377 (22): 2167–79.Zeiser R., Fatoum H., Hashmi S.K. A personalized, organ-based approach to the treatment of chronic steroid-refractory gfart-versus-host disease. Blood Rev 2024; 63: 101142.Bachier C.R., Aggarwal S.K., Hennegan K., Milgroom A., Francis K., Dehipawala S., Rotta M. Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis. Transpl Cell Ther 2021; 27 (6): 504. e1–6.Wingard J.R., Majhail N.S., Brazauskas R., Wang Z., Sobocinski K.A., Jacobsohn D., et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29 (16): 2230–9.Bhatia S., Francisco L., Carter A., Sun C.-L., Scott Baker K., Gurney J.G., et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the bone marrow transplant survivor study. Blood 2007; 110 (10): 3784–92.DeFilipp Z., Alousi A.M., Pidala J.A., Carpenter P.A., Onstad L.E., Arai S., et al. Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the chronic GVHD consortium. Blood Adv 2021; 5 (20): 4278–84.Majhail N.S., Brazauskas R., Rizzo J.D., Sobecks R.M., Wang Z., Horowitz M.M., et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011; 117 (1): 316–22.Armenian S.H., Chemaitilly W., Chen M., Chow E.J., Duncan C.N., Jones L.W., et al. National Institutes of Health hematopoietic cell transplantation late effects initiative: the cardiovascular disease and associated risk factors working group report. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2017; 23 (2): 201–10.Arai S., Arora M., Wang T., Spellman S.R., He W., Couriel D.R., et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2015; 21 (2): 266–74.Inamoto Y., Storer B.E., Petersdorf E.W., Nelson J.L., Lee S.J., Carpenter P.A., et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood 2013; 121 (25): 5098–103.Rodrıguez-Gil A., Carrillo-Cruz E., Marrero-Cepeda C., Rodriguez G., Perez-Simon J.A. Effect of vitamin D on graft-versus-host disease. Biomedicines 2022; 10 (5): 987.Jagasia M.H., Greinix H.T., Arora M., Williams K.M., Wolff D., Cowen E.W., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21 (3): 389–401.Pidala J., Vogelsang G., Martin P., Chai X., Storer B., Pavletic S., et al. Overlap subtype of chronic graftversus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. Haematologica 2012; 97 (3): 451–8.Schoemans H.M., Lee S.J., Ferrara J.L., Wolff D., Levine J.E., Schult K.R., et al.; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health) − CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 2018; 53 (11): 1401–15.Filipovich A.H., Weisdorf D., Pavletic S., Socie G., Wingard J.R., Lee S.J., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11 (12): 945–56.MacDonald K.P., Hill G.R., Blazar B.R. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 2017; 129 (1): 13–21.Yi T., Chen Y., Wang L., Du G., Huang D., Zhao D., et al. Reciprocal diff entiation and tissue-specifi pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009; 114 (14): 3101–12.Carlson M.J., West M.L., Coghill J.M., Panoskaltsis-Mortari A., Blazar B.R., Serody J.S. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009; 113 (6): 1365–74.Carlson M.J., West M.L., Coghill J.M., Panoskaltsis-Mortari A., Blazar B.R., Serody J.S. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009; 113 (6): 1365–74.Serody J.S., Hill G.R. The IL-17 differentiation pathway and its role in transplant outcome. Biol Blood Marrow Transplant 2012; 18 (1 Suppl): S56–61.Jin H., Ni X., Deng R., Song Q., Young J., Cassady K., et al. Antibodies from donor B cells perpetuate cutaneous chronic graft-versushost disease in mice. Blood 2016; 127 (18): 2249–60.Alexander K.A., Flynn R., Lineburg K.E., Kuns R.D., Teal B.E., Olver S.D., et al. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest 2014; 124 (10): 4266–80.Erbel C., Akhavanpoor M., Okuyucu D., Wangler S., Dietz A., Zhao L., et al. IL-17A infl es essential functions of the monocyte/ macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol 2014; 193 (9): 4344–55.Zorn E., Kim H.T., Lee S.J., Floyd B.H., Litsa D., Arumugarajah S., et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graftversus-host disease. Blood 2005; 106 (8): 2903–11.Soiffer R.J., Lerademacher J., Ho V., Kan F., Artz A., Champlin R.E., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117 (25): 6963–70.Devine S.M., Carter S., Soiffer R.J., Pasquini M.C., Hari P.N., Stein A., et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 2011; 17 (9): 1343–51.Luznik L., Bolaños-Meade J., Zahurak M., Chen A.R., Smith B.D., Brodsky R., et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graftversus-host disease. Blood 2010; 115 (16): 3224–30.Raj K., Pagliuca A., Bradstock K., Noriega V., Potter V., Streetly M., et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014; 20 (6): 890–5.Kitko C.L. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report Transplant Cell Ther 2021; 27 (7): 545–57.Скворцова Ю.В., Новичкова Г.А., Масчан А.А. Новое в патогенезе, диагностике и лечении хронической реакции «трансплантат против хозяина» после аллогенной ТГСК. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии 2018; 17 (2): 121–35. DOI: 10.24287/1726-1708-2018-172-121-135 [Skvortsova Yu.V., Novichkova G.A., Maschan A.A. New advances in pathogenesis, diagnostic and treatment of chronic graftversus-host disease after allogeneic hematopoietic stem cell transplantation. Pediatric Hematology/Oncology and Immunopathology 2018; 17 (2): 121–35. (In Russ.)].Скворцова Ю.В., Новичкова Г.А., Масчан А.А. Новое в патогенезе, диагностике и лечении хронической реакции «трансплантат против хозяина» после аллогенной ТГСК. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии 2018; 17 (2): 121–35. DOI: 10.24287/1726-1708-2018-172-121-135Wolff D., Schleuning M., von Harsdorf S., Bacher U., Gerbitz A., Stadler M., et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2011; 17 (1): 1–17.Carpenter P.A., Kitko C.L., Elad S., Flowers M.E., Gea-Banacloche J.C., Halter J.P., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2015; 21 (7): 1167–87.Martin P.J., Inamoto Y., Carpenter P.A., Lee S.J., Flowers M.E. Treatment of chronic graft-versus-host disease: Past, present and future. Korean J Hematol 2011; 46 (3): 153–63.Flowers M.E., Martin P.J. How we treat chronic graft-versus-host disease. Blood 2015; 125 (4): 606–15.Flowers M.E., Storer B., Carpenter P., Rezvani A.R., Vigorito A.C., Campregher P.V., et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14 (12): 1380–4.Inamoto Y., Flowers M.E., Sandmaier B.M., Aki S.Z., Carpenter P.A., Lee S.J., et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood 2014; 124 (8): 1363–71.Greinix H.T., Worel N., Just U., Knobler R. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci 2014; 50 (3): 349–57.Flowers M.E., Apperley J.F., van Besien K., Elmaagacli A., Grigg A., Reddy V., et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versushost disease. Blood 2008; 112 (7): 2667–74.Olivieri A., Cimminiello M., Corradini P., Mordini N., Fedele R., Selleri C., et al. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 2013; 122 (25): 4111–8.de Masson A., Bouaziz J.D., Peffault de Latour R., Wittnebel S., Ribaud P., Rubio M.T., et al. Limited effi y and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. Blood 2012; 120 (25): 5089–90.Inamoto Y., Flowers M.E. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol 2011; 18 (6): 414–20.Penack O., Marchetti M., Ruutu T., Aljurf M., Bacigalupo A., Bonifazi F., et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantion Lancet Haematol 2020; 7 (2): e157–67.Couriel D., Carpenter P.A., Cutler C., Bolaños-Meade J., Treister N.S., Gea-Banacloche J., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12 (4): 375–96.[Electronic resource] URL: http://asbmt.affiniscape.com/associations/11741/files/DispensaryGuidelines.pdf) (accessed 03.06.2020).Vigorito A.C., Campregher P.V., Storer B.E., Carpenter P.A., Moravec C.K., Kiem H.P., et al. Evaluation of NIH consensus criteria for classifi of late acute and chronic GVHD. Blood 2009; 114 (3): 702–8.Vigorito A.C., Campregher P.V., Storer B.E., Carpenter P.A., Moravec C.K., Kiem H.P., et al. Evaluation of NIH consensus criteria for classifi of late acute and chronic GVHD. Blood 2009; 114 (3): 702–8.